迪安诊断涨2.23%，成交额1.17亿元，主力资金净流入22.32万元

Core Viewpoint - Dian Diagnostics has shown a significant stock price increase of 48.75% year-to-date, despite a recent decline in revenue and net profit [1][2]. Group 1: Stock Performance - On November 18, Dian Diagnostics' stock rose by 2.23%, reaching 16.52 CNY per share, with a trading volume of 1.17 billion CNY and a turnover rate of 1.43%, resulting in a total market capitalization of 103.25 billion CNY [1]. - The stock has experienced a slight increase of 0.06% over the last five trading days, a 7.97% increase over the last 20 days, and a minor decline of 0.12% over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on February 17 [1]. Group 2: Financial Performance - For the period from January to September 2025, Dian Diagnostics reported a revenue of 75.66 billion CNY, reflecting a year-on-year decrease of 18.28%, while the net profit attributable to shareholders was 56.70 million CNY, down 56.67% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 10.99 billion CNY in dividends, with 7.12 billion CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Dian Diagnostics was 45,700, a decrease of 5.45% from the previous period, with an average of 10,974 shares held per shareholder, an increase of 5.76% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 10.56 million shares, a decrease of 4.23 million shares from the previous period [3].